This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bapineuzumab (IV and SQ)
Johnson & Johnson
Drug Names(s): AAB-001, ELN115727
Description: Bapineuzumab is an antibody that binds to and clears beta amyloid peptide (specifically it targets the N-terminus portion of the peptide). It is designed to provide antibodies to beta amyloid directly to the patient, rather than requiring the patient to mount their own immune response to beta amyloid.
Animal studies have shown that this approach is equally effective in clearing beta amyloid from the brain as traditional active immunization methods. By providing such a “passive immunization” approach for treatment of Alzheimer’s disease, it is believed that the benefits demonstrated with Elan's suspended drug AN-1792 will be retained, while the safety concerns will be greatly reduced or eliminated due to the absence of stimulation of the patient’s immune response to beta amyloid.
Bapineuzumab is being tested in both an intravenous (IV) and subcutaneous (SQ) formulation. The IV formulation is given as an infusion every 13 weeks.
Deal Structure: Elan and Wyeth's Alzheimer's Immunotherapy Program (AIP) is a 50:50 collaboration to research, develop and commercialize an immunotherapeutic approach that may be used for the treatment of mild to moderate AD and possibly to prevent the onset of the disease. AIP programs include bapineuzumab.
In May 2008, Intellect Neurosciences announced that the Company has entered into a license agreement with Wyeth and Elan regarding certain of Intellect's patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease. Under the terms of the agreement, Wyeth and Elan may pay Intellect potential future milestone payments and royalties based on sales of potential products, if it is determined that they are covered by patents that issue from Intellect's patent applications.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued...See full deal structure in Biomedtracker
Partners: Pfizer Inc. Perrigo Company PLC PDL BioPharma, Inc. Intellect Neurosciences, Inc.
Bapineuzumab (IV and SQ) News
Pink Sheet Beyond Bapi: Alzheimer’s Pipeline Runs Deep
Additional information available to subscribers only: